Professor Alberto Zambon received his MD degree in 1988 from the University of Padua. He is board certified in endocrinology and metabolism (1993), and holds a PhD in gerontology from the University of Padua (1998).
Professor Zambon was a Post-Doctoral Fellow in Endocrinology and Metabolism at the Division of Endocrinology, Metabolism and Nutrition, School of Medicine, University of Washington, Seattle, (1991-1993 and again 1995-1998), where, in 1999, he was appointed Acting Assistant Professor of Medicine and currently holds a position of Affiliate Assistant Professor of Medicine.
Professor Zambon received an AHA fellowship award (1996-97), the 1997 Young Faculty Award of the Western Society for Clinical Investigation (US), the Paul Beeson Physician Faculty Scholarship of American Federation For Aging Research (1998-2001), the Merck Young Investigators on Lipid Research Award for outstanding research contribution (1999) and the Award for Outstanding Scientific Contributions in Medical Research (2000 and 2001) from the School of Medicine, University of Padua, Italy. His main clinical interests are in the care of patients with premature atherosclerosis and in patients with lipid disorders. Professor Zambon is currently a member of the national board of the Italian Atherosclerosis Society Foundation. He is a member of the Italian Atherosclerosis Society (SISA), the European Atherosclerosis Society (EAS), Gold Heart Member of the AHA and FAHA, and the International Atherosclerosis Society (IAS). He has served as member of the the International Advisory Board for the XV and XVI International Atherosclerosis Society (IAS) Symposiums. Professor Zambon is currently a member of the Executive Board of the EAS.

Contributions

Rebuttals: Triglycerides and CVD: Where do we stand? Pro & Contra91th EAS Congress 2023Triglycerides and CVD: Where do we stand? Pro & ContraWhy we should target apoB lowering not TG or remnants91th EAS Congress 2023Triglycerides and CVD: Where do we stand? Pro & ContraPanel Discussion: Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?91th EAS Congress 2023Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?Recent trials with Omega 3 lessons to be learned91th EAS Congress 2023Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?Science versus reality: Real life Clinical Cases89th EAS Congress 2021(ReviewGuidelinesTreatmentHypolipidemic drugs)Will precision medicine help tailor dyslipidemia treatment?EAS 2017 AC on Precision Medicine in AThe value of omega 3 - from biology to clinical practice88th EAS Congress 2020What is the price to pay if we are not at goal?87th EAS Congress 2019How to treat diabetic dyslipidaemia85th EAS Congress 2017Atherogenic dyslipidemia (AD)85th EAS Congress 2017